New Startup iOrganBio Launches with $2M for AI-Based Cell Manufacturing Platform, CellForge™
The company’s AI-powered CellForge™ platform aims to streamline and scale the production of engineered human cells and organoids.
Manufacturing
New Korean Stem Cell Hub Coming to Baltimore, Focused on OA and Alzheimer’s Research
Nature Cell’s new facility will focus on stem cell therapeutics, research, and manufacturing, supported by the Maryland Stem Cell Research Fund.
Jackson Laboratory Acquires New York Stem Cell Foundation to Boost Biomedical Research and Precision Medicine Development
The combined resources aim to accelerate early-stage research, driven by iPSCs, robotics, and AI.
REPROCELL Awarded Maryland Stem Cell Fund Grant for Manufacturing Development
The new grant will help expand REPROCELL’s stem cell manufacturing capabilities and support Maryland’s growing regenerative medicine sector.
Made Scientific and Streamline Bio Partner to Advance AI-Powered Robotic Cell Therapy Manufacturing
The collaboration aims to automate cell therapy production, addressing manufacturing complexity, cost, and product consistency using AI-driven robotics.
TheWell Bioscience Introduces VitroGel® NEURON, a Synthetic Hydrogel Enhancing Neuronal Cell Culture
Designed for 2D and 3D cultures, this platform aims to offer greater consistency and scalability in neuronal research.
ScaleReady Awards Nearly $2 Million in Grants for Cell and Gene Therapy Production in California
Eight California research centers receive funding to expand cell and gene therapy manufacturing.
RoosterBio Helping Secretome Therapeutics Scale Cardiac Cell Therapy Manufacturing
RoosterBio and Secretome advance scalable cell therapy manufacturing with a new 50L bioreactor process for STM-01 clinical trials.
Mytos Nabs Cell Manufacturing Deals with StemSight, Rinri Therapeutics, and Novadip
Mytos has developed an automated cell manufacturing platform to serve the cell therapy industry as it matures
MaxCyte Partners with Adicet Bio for Gene Therapy Development Using Electroporation Technology
The agreement gives Adicet access to MaxCyte’s technology for developing scalable, non-viral gene-edited cell therapies.
